View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 7, 2022

Helixmith reports Phase IIA data for Engensis to treat ALS

According to the findings from the trial in ALS patients, Engensis was found to be safe and well tolerated.

Helixmith has reported topline data from a Phase IIA clinical trial of Engensis (VM202) in people with amyotrophic lateral sclerosis (ALS). 

The double-blind, placebo-controlled, multicentre trial was carried out at five sites, with four in the US and one in Korea.

It enrolled 18 participants, who were randomised into a 2:1 ratio to receive either Engensis or a placebo. 

In the trial, three treatments of Engensis or a placebo were administered in the upper and lower limbs on months zero, two, and four.

A treatment comprised two cycles of injections of 64mg Engensis or a placebo given at a gap of two weeks. 

According to the trial data, Engensis was found to be safe and well tolerated. 

No variations between the Engensis and the placebo arms in the frequency of treatment-emergent adverse events (TEAEs) were reported. 

50% of the subjects in the Engensis arm had injection site reactions versus 66.7% in the placebo group. 

These findings indicated that a high dose and repeated treatments with Engensis were safe and well tolerated in trial subjects, providing enhanced flexibility in developing dosing schemes for clinical trials in the future.

The company could not compare the efficacy between the Engensis and the placebo arms, as the size of the trial was small and four subjects dropped out early.

An advanced pipeline candidate of the company, Engensis is a plasmid deoxyribonucleic acid (DNA) therapy encoding human HGF.

This gene therapy is administered intramuscularly.

As part of the trial, muscle biopsy samples were obtained from trial subjects and will undergo histological and molecular biological assessments using RNA-Seq.

A fatal neurodegenerative ailment, ALS impacts upper and lower motor neurons. It leads to progressive paralysis and death eventually because of respiratory failure.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena